GHRP-6 10mg

What is GHRP-6 (10mg)?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that belongs to the class of compounds known as growth hormone secretagogues. These peptides have been extensively studied in laboratory settings for their potential to influence growth hormone signaling pathways. GHRP-6 contains six amino acids arranged in a specific sequence designed to mimic natural peptide signaling mechanisms, which are commonly studied in endocrine research. In research environments, GHRP-6 is often investigated for its interactions with biological pathways related to metabolism and growth-related cellular signaling. What are the key features of GHRP-6 (10mg)? GHRP-6 (10mg) is provided as a lyophilized peptide powder in a sealed research vial. The 10 mg format is often selected by laboratories conducting extended experiments or requiring multiple preparations from a single vial. Key product features include:

• Peptide classification: Synthetic growth hormone releasing peptide
• Sequence length: 6 amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)
• CAS Number: 87616-84-0
• Chemical Formula: C₄₆H₅₆N₁₂O₆
• Molecular weight:  873.03 g/mol
• Purity: ≥98%, verified using HPLC and MS analysis
• Format: 10 mg lyophilized peptide supplied in a sterile research vial
• Research applications: Investigated in endocrine signaling and metabolic pathway studies

For laboratory research use only.

How is GHRP-6 (10mg) synthesized?

GHRP-6 is produced by solid-phase peptide synthesis (SPPS), a standard method for synthesizing short peptides with precise amino acid sequences. During this process, individual amino acids are sequentially added to a growing peptide chain anchored to a solid support resin, thereby enabling the controlled assembly of the six-amino-acid sequence. Once synthesis is complete, the peptide is cleaved from the resin, purified, and lyophilized into a stable powder suitable for laboratory storage. Analytical verification typically involves high-performance liquid chromatography (HPLC) to confirm purity and mass spectrometry (MS) to verify the peptide’s molecular weight and structural identity. These procedures ensure consistency and reliability for research purposes.

What is GHRP-6 (10mg) being studied for? What are its possible benefits?

In scientific research, GHRP-6 has been investigated for its potential role in growth hormone signaling and metabolic regulation. Studies have explored how growth hormone secretagogues, such as GHRP-6, may influence biological pathways involved in endocrine function, particularly those related to growth factor release and cellular metabolism. GHRP-6 has also been studied in experimental models examining angiogenesis (the formation of new blood vessels), cellular repair processes, and protein metabolism. Some laboratory findings suggest that peptides in this class may interact with pathways involved in tissue growth and regenerative signaling. These areas of research are still under investigation, with current knowledge derived from preclinical studies and controlled laboratory experiments.

How does GHRP-6 (10mg) work in research studies?

In experimental studies, GHRP-6 is believed to interact with systems that regulate growth hormone signaling pathways. In laboratory models, peptides such as GHRP-6 have been studied for their ability to modulate signaling mechanisms that contribute to the release of growth-related factors. These signaling interactions may impact cellular processes such as protein synthesis, metabolic signaling, and cell growth. Researchers are continuing to explore how these peptides interact with endocrine tissues and intracellular signaling networks. Current understanding is largely based on in vitro (test-tube) experiments and animal model studies, in which the peptide’s activity can be observed under controlled conditions.

What dosing information exists for GHRP-6 (10mg)?

The available literature on GHRP-6 primarily reports dosing parameters used in preclinical and laboratory studies. In certain animal models, the peptide has been studied at doses ranging from 10 to 100 µg/kg, depending on the study's experimental design and objectives. In cell culture experiments, GHRP-6 has been evaluated at nanomolar to micromolar concentrations to study cellular responses and signaling pathways. These concentrations reflect conditions used in controlled laboratory research. There are no established dosing guidelines for human or veterinary applications, and experimental concentrations should only be interpreted within the context of scientific research.

How should GHRP-6 (10mg) be stored and handled?

To preserve peptide integrity, GHRP-6 (10mg) should be stored in its lyophilized form at –20 °C. The vial should remain sealed and protected from light and moisture until ready for laboratory use. If the peptide is reconstituted with an appropriate sterile solvent, short-term storage at 2–8 °C is typically recommended. Researchers should minimize repeated freeze-thaw cycles, as these can affect peptide integrity. Lyophilized peptides should be stored in a sealed container, protected from light and moisture, until reconstitution.

Where can I read more research about GHRP-6 (10mg)?

1. de Sá LB, Nascif SO, Correa-Silva SR, et al. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. Metabolism. 2010;59(10):1536-1542. doi:10.1016/j.metabol.2010.01.021
2. Catalina PF, Mallo F, Andrade MA, García-Mayor RV, Diéguez C. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J Clin Endocrinol Metab. 1998;83(10):3663-3667. doi:10.1210/jcem.83.10.5153
3. Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46. doi:10.1016/j.ejps.2012.10.006
4. Oliveira JH, Vieira JG, Abucham J, Lengyel AM. GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP. J Endocrinol Invest. 2003;26(3):230-235. doi:10.1007/BF03345162

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.